Here, we characterized the expression of MET (including METex14SM and CNV), PD-L1, and CD44 in five GC cells using targeted NGS gene panel data and immunoblotting and further evaluated the differential susceptibility of the MET inhibitor tepotinib based on dose-dependent viability, cell death, and migration. This evidence concerns the gene CD44 and gastric cancer.